Outcomes of Intravitreal Bevacizumab in Choroidal Neovascularization in Vogt-Koyanagi-Harada Disease– A Prospective Study

REFERENCES

• Moorthy RS, Inomata H, Rao NA. Major review Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol. 1995;39:265–292. doi:10.1016/S0039-6257(05)80105-5.
   PubMed Web of Science ®Google Scholar
• da Silva FT, Hirata CE, Olivalves E, Oyamada MK, Yamamoto JH. Fundus-based and electroretinographic strategies for stratification of late-stage Vogt-Koyanagi-Harada disease patients. Am J Ophthalmol. 2009;148:939–945. doi:10.1016/j.ajo.2009.06.029.
   PubMed Web of Science ®Google Scholar
• Lertsumitkul S, Whitcup SM, Nussenblatt RB, Chan CC. Subretinal fibrosis and choroidal neovascularization in Vogt-Koyanagi-Harada syndrome. Graefes Arch Clin Exp Ophthalmol. 1999;237:1039–1045. doi:10.1007/s004170050342.
   PubMed Web of Science ®Google Scholar
• Sukavatcharin S, Tsai JH, Rao NA. Vogt-Koyanagi-Harada disease in Hispanic patients. Int Ophthalmol. 2007;27:143–148. doi:10.1007/s10792-006-9017-6.
   PubMedGoogle Scholar
• Read RW, Rechodouni A, Butani N, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2001;131:599–606. doi:10.1016/S0002-9394(01)00937-0.
   PubMed Web of Science ®Google Scholar
• Sakata VM, Lavezzo MM, da Silva FT, et al. Full-field electroretinogram behavior in Vogt-Koyanagi-Harada disease: a 24-month longitudinal study in patients from acute onset evaluated with multimodal analysis. Graefe’s Arch Clin Exp Ophthalmol. 2019;257:2285–2295. doi:10.1007/s00417-019-04440-w.
   PubMed Web of Science ®Google Scholar
• Dhingra N, Kelly S, Majid MA, Bailey CB, Dick AD. Inflammatory choroidal neovascular membrane in posterior uveitis, pathogenesis and treatment. Indian J Ophthalmol. 2010;58:3–10. doi:10.4103/0301-4738.58467.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Invernizzi A, Singh RB, et al. An update on inflammatory choroidal neovascularization: epidemiology, multimodal imaging, and management. J Ophthalm Inflam Infect. 2018;8:13. doi:10.1186/s12348-018-0155-6.
   PubMed Web of Science ®Google Scholar
• Oh H, Takagi H, Takagi C, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1999;40:1891–1898.
   PubMed Web of Science ®Google Scholar
• Perentes Y, Van Tran T, Sickenberg M, Herbort CP. Subretinal neovascular membranes complicating uveitis: frequency, treatments, and visual outcome. Ocul Immunol Inflamm. 2005;13:219–224. doi:10.1080/09273940490518883.
   PubMed Web of Science ®Google Scholar
• Adán A, Mateo C, Wolley-Dod C. Surgery for subfoveal choroidal neovascularization in toxoplasmic retinochoroiditis. Am J Ophthalmol. 2003;135:386–387. doi:10.1016/S0002-9394(02)01947-5.
   PubMed Web of Science ®Google Scholar
• Dadgostar H, Waheed N. The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. Eye (Lond). 2008;22:761–767. doi:10.1038/eye.2008.86.
   PubMed Web of Science ®Google Scholar
• Arias L, Planas N, Prades S, et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol. 2008;92:1035–1039. doi:10.1136/bjo.2007.130260.
   PubMed Web of Science ®Google Scholar
• Battaglia Parodi M, Iacono P, La Spina C, et al. Intravitreal bevacizumab for nonsubfoveal choroidal neovascularization associated with angioid streaks. Am J Ophthalmol. 2014;157:374–377. doi:10.1016/j.ajo.2013.10.015.
   PubMed Web of Science ®Google Scholar
• Rouvas A, Petrou P, Douvali M, Ntouraki A, Vergados I, Georgalas IM. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Retina. 2011;31:871–879. doi:10.1097/IAE.0b013e3182003ca8.
   PubMed Web of Science ®Google Scholar
• Wu L, Evans T, Saravia M, Schlaen A, Couto C. Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome. Jpn J Ophthalmol. 2009;53:57–60. doi:10.1007/s10384-008-0600-4.
   PubMed Web of Science ®Google Scholar
• Kolomeyer AM, Roy MS, Chu DS. The use of intravitreal ranibizumab for choroidal neovascularization associated with Vogt-Koyanagi-Harada syndrome. Case Rep Med. 2011;2011:747648. doi:10.1155/2011/747648.
   PubMedGoogle Scholar
• Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for. Am J Ophthalmol. 2001;131:647–652. doi:10.1016/S0002-9394(01)00925-4.
   PubMed Web of Science ®Google Scholar
• Ganesh S, Ahmed A, Biswas J. Analysis of the clinical profile and management of inflammatory choroidalchor neovascular membranes in uveitic eyes: a study form a tertiary referral center. Ocul Immunol Inflamm. 2019;27:424–434. doi:10.1080/09273948.2017.1375119.
   PubMed Web of Science ®Google Scholar
• Nowilaty SR, Bouhaimed M. Photodynamic therapy for subfoveal choroidal neovascularisation in Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2006;90:982–986. doi:10.1136/bjo.2006.091538.
   PubMed Web of Science ®Google Scholar
• Mansour AM, Arevalo JF, Fardeau C, et al. Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization. Can J Ophthalmol. 2012;47:269–274. doi:10.1016/j.jcjo.2012.03.042.
   PubMed Web of Science ®Google Scholar
• Roy R, Saurabh K, Bansal A, Kumar A, Majumdar AK, Paul SS. Inflammatory choroidal neovascularization in Indian eyes: etiology, clinical features, and outcomes to anti-vascular endothelial growth factor. Indian J Ophthalmol. 2017;65:295–300. doi:10.4103/ijo.IJO_262_16.
   PubMed Web of Science ®Google Scholar
• D’Souza P, Ranjan R, Babu U, Kanakath AV, Saravanan VR. Inflammatory choroidal neovascular membrane: long-term visual and anatomical outcomes after intravitreal anti–vascular endothelial growth factor therapy. Retina. 2018;38:1307–1315. doi:10.1097/IAE.0000000000001710.
   PubMed Web of Science ®Google Scholar
• Lott MN, Schiffman JC, Davis JL. Bevacizumab in inflammatory eye disease. Am J Ophthalmol. 2009;149:711–717. doi:10.1016/j.ajo.2009.06.010.
   Google Scholar
• Raffa L, Bawazeer A. Intravitreal bevacizumab injection in a 14-year-old Vogt-Koyanagi-Harada patient with choroidal neovascular membrane. Can J Ophthalmol. 2009;44:615–616. doi:10.3129/i09-144.
   PubMed Web of Science ®Google Scholar
• Pai S, Hebri SP, Lootah AM. Management of recurrent inflammatory choroidal neovascular membrane secondary to Vogt-Koyanagi-Harada syndrome, using combined intravitreal injection of bevacizumab and triamcinolone acetate. Indian J Ophthalmol. 2012;60:551–552. doi:10.4103/0301-4738.103795.
   PubMed Web of Science ®Google Scholar
• Mansour AM, Arevalo JF, Ziemssen F, et al. Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol. 2009;148:310–316. doi:10.1016/j.ajo.2009.03.023.
   PubMed Web of Science ®Google Scholar
• Tran THC, Fardeau C, Terrada C, et al. Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis. Graefes Arch Clin Exp Ophthalmol. 2008;246:1685–1692. doi:10.1007/s00417-008-0906-4.
   PubMed Web of Science ®Google Scholar
• Bacsal K, Wen DSH, Chee S-P. Concomitant choroidal inflammation during anterior segment recurrence in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2008;145:480–486. doi:10.1016/j.ajo.2007.10.012.
   PubMed Web of Science ®Google Scholar
• Baxter SL, Pistilli M, Pujari SS, et al. Risk of Choroidal Neovascularization among the Uveitides. Am J Ophthalmol. 2013;156:468–477. doi:10.1016/j.ajo.2013.04.040.
   PubMed Web of Science ®Google Scholar
• Adán A, Mateo C, Navarro R, Bitrian E, Casaroli-Marano RP. Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina. 2007;27:1180–1186. doi:10.1097/IAE.0b013e31815e9834.
   PubMed Web of Science ®Google Scholar
• Wachtlin J, Heimann H, Behme T, Foerster M. Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefe’s Arch Clin Exp Ophthalmol. 2003;241:899–906. doi:10.1007/s00417-003-0734-5.
   PubMed Web of Science ®Google Scholar